WDA
IMRX icon

Wendell David Associates’s Immuneering IMRX Stock Holding History

Wendell David Associates’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$61K Hold
15,000
– – 0.01% 150
2026
Q2 		$75K Hold
15,000
– – 0.01% 154
2026
Q1 		$79K Hold
15,000
– – 0.01% 150
2025
Q4 		$99K Hold
15,000
– – 0.01% 148
2025
Q3 		$105K Buy
+15,000
New +$77.8K 0.01% 148

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Sanofi
Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $444M AUM 151.5% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return
Levin Capital Strategies
Levin Capital Strategies New York $1.42B AUM 19.05% 1-Year Est. Return
PVG Asset Management
PVG Asset Management Golden, Colorado $147M AUM 52.72% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $106B AUM 21.33% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Wendell David Associates's IMRX Position: Q3 2026 in Review

Wendell David Associates held its Immuneering (IMRX) position steady in Q3 2026 at 15,000 shares worth $61K. The position accounts for 0.01% of the portfolio, ranked #150.

Wendell David Associates first reported a position in IMRX in Q3 2025 and has held it in 5 quarters since. The position peaked at $105K in Q3 2025. 54 funds tracked by Wall St. Rank hold IMRX as of Q3 2026.

  • Wendell David Associates held 15,000 shares of Immuneering worth $61K as of Q3 2026.
  • Wendell David Associates left its Immuneering share count unchanged in Q3 2026.
  • Immuneering made up 0.01% of Wendell David Associates's portfolio in Q3 2026, its #150 holding.
  • Wendell David Associates first reported a position in Immuneering in Q3 2025 and has held it in 5 quarters since.
  • Wendell David Associates's Immuneering position peaked at $105K in Q3 2025.
  • 54 funds tracked by Wall St. Rank held Immuneering as of Q3 2026.

Based on Wendell David Associates's 13F filing for Q3 2026, filed 27 Oct 2026.